Last updated: August 11, 2025
Introduction
Patent ES2694158, titled "Pharmaceutical compositions for the treatment of diseases related to the nervous system," is a Spanish patent with implications in neurotherapeutics. It exemplifies strategic innovation in neurodegenerative and neuropsychiatric disorder treatments, aligning with global efforts to address unmet medical needs in neurological health. This analysis delineates the scope and claims of ES2694158 and contextualizes its position within the broader patent landscape, offering insights for industry stakeholders and R&D strategists.
Patent Overview
-
Filing and Granting Timeline: The application was filed on February 20, 2017, and granted on October 24, 2019.
-
Applicant: The patent was filed by Innovative Neuropharma S.L., a company specializing in neurotherapeutic compounds.
-
Patent Term: Expected expiry around 2037, considering the 20-year patent term from filing.
-
Patent Classification: Primarily falls under A61K (preparations for medical, dental, or cosmetic purposes), with specific subcategories pointing towards nervous system disorder treatments.
Scope and Claims Analysis
1. Overall Scope
The patent claims focus on a pharmaceutical composition comprising a specific benzodiazepine derivative, combined with a phospholipid carrier. The innovation aims to improve drug delivery and therapeutic efficacy for neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.
2. Key Claims Breakdown
Claim 1 (Independent Claim):
Defines a pharmaceutical composition comprising:
- A benzodiazepine derivative, specifically (1,4)-benzodiazepine compound with a defined chemical structure.
- An effective amount of a phospholipid carrier selected from phosphatidylcholine, phosphatidylserine, or mixtures thereof.
- The composition is formulated for intranasal administration to target central nervous system disorders.
Implication: The broad scope indicates protection for the combination of particular benzodiazepines with phospholipids via intranasal delivery, emphasizing neurotherapeutic usage.
Claim 2:
Specifies the chemical structure of the benzodiazepine derivative, including substitution patterns and stereochemistry, narrowing the scope to compounds with certain pharmacological profiles.
Claim 3:
Addresses dosage ranges and administration frequency for the composition, providing practical therapeutic parameters.
Claim 4-10:
Cover specific embodiments such as:
- Specific phospholipids (e.g., phosphatidylcholine).
- Additional excipients or preservatives.
- Stabilization methods.
- Manufacturing processes for the pharmaceutical composition.
Summary: These claims refine the invention’s scope but remain linked to the core combination described in Claim 1.
Patent Landscape Context
3. State of the Art and Prior Art Landscape
The patent landscape in neuropharmaceuticals featuring benzodiazepine derivatives and lipid-based delivery systems reveals a complex web of overlapping IP. Notable prior art includes:
- Lipid-based CNS drug delivery patents: Several patents (e.g., WO2013018990) protect phospholipid carriers for intranasal or transdermal delivery.
- Nootropic and neuroprotective agents: Prior patents focus on benzodiazepine derivatives for anxiolytic or sedative effects (e.g., US20140233456).
- Combination approaches: However, specific combinations involving benzodiazepines with phospholipids for intranasal neurotherapy are less prevalent.
4. Patent Family and International Coverage
Beyond Spain, EP and PCT applications have been filed, indicating an intent for European and global protection. Notably:
- An EP application (EP3478901) claiming similar compositions was filed in 2018, with some overlapping claims but narrower chemical scope.
- The applicant has also sought protection in Mexico, Colombia, and Brazil, aligning with market expansion strategies.
5. Freedom-to-Operate Considerations
While current prior art does not explicitly protect the exact combination and chemical structures claimed, the presence of overlapping lipid delivery patents warrants thorough freedom-to-operate analyses before commercial deployment. The strategic inclusion of specific benzodiazepine derivatives and intranasal application aims to carve out distinct IP territory.
Claims and Patent Strategy Insights
- The patent’s broad claims on benzodiazepine and phospholipid combinations align with licensing and collaboration opportunities in neurotherapeutic pipelines.
- The intranasal delivery route adds a layer of innovation, addressing limitations of systemic administration in crossing the blood-brain barrier.
- Focused claims on composition stability and manufacturing processes serve to extend patent life and provide defensive buffers.
Regulatory and Commercial Considerations
- Patent protection supports market exclusivity for a potentially disruptive intranasal neurodrug.
- The composition’s specificity—benzodiazepine derivatives combined with phospholipids—may facilitate regulatory approval pathways for novel formulations.
- The emerging neurodegenerative disease market underscores the patent’s commercial relevance, notably for treating Alzheimer's and Parkinson’s.
Key Competitor and Patent Landscape Dynamics
- Companies like AbbVie, Teva, and Janssen hold patents on benzodiazepine derivatives and lipid nanocarriers, but primarily for different indications or delivery routes.
- The novelty and inventive step of ES2694158 hinge on the specific combination of a benzodiazepine derivative with a phospholipid carrier via intranasal route for CNS disorders.
Concluding Remarks
Patent ES2694158's claims broadly encompass compositions combining specific benzodiazepine derivatives with phospholipids formulated for intranasal administration. Its strategic positioning fills a niche in neurotherapeutic delivery, aligning with ongoing innovations in lipid-based CNS drug delivery systems. The patent’s scope appears robust within the scope of chemical composition and formulation, with a carefully defined claim set designed to withstand prior art challenges.
Stakeholders should monitor the patent family’s extensions to European and international jurisdictions, assess freedom-to-operate landscapes, and explore licensing opportunities in high-growth neurodegenerative markets.
Key Takeaways
- Comprehensive protection: ES2694158 secures broad rights over benzodiazepine-phospholipid compositions for intranasal CNS delivery.
- Strategic innovation: Focused on enhancing drug delivery efficacy for neurodegenerative diseases, addressing key market gaps.
- Patent landscape positioning: Converges with lipid carrier patents but offers unique claims on specific combinations and formulations.
- Future opportunities: Potential licensing, collaboration, and development pathways hinge on ongoing patent extensions and clinical validation.
- Risk management: Vigilant mapping of similar patent rights is essential to secure freedom-to-operate before commercialization.
FAQs
Q1: What makes ES2694158 unique compared to prior art?
It claims specific benzodiazepine derivatives combined with phospholipids, formulated for intranasal administration targeting CNS disorders, which is less common in existing lipid-based neurodelivery patents.
Q2: Does the patent cover all benzodiazepines?
No. The claims specify particular benzodiazepine derivatives with defined chemical structures, limiting scope to those compounds.
Q3: Can this patent be licensed for commercial drug development?
Yes. Its broad claims and strategic positioning make it an attractive licensing opportunity for companies developing intranasal neurotherapeutics.
Q4: Are there any known challenges concerning patent infringement?
Potential overlaps with existing lipid and CNS delivery patents necessitate careful freedom-to-operate assessments before market entry.
Q5: What is the significance of the intranasal administration route in this patent?
It addresses the blood-brain barrier challenge, facilitating direct CNS drug delivery, which enhances therapeutic efficacy and reduces systemic side effects.
References
[1] Spanish Patent ES2694158, "Pharmaceutical compositions for the treatment of diseases related to the nervous system," granted October 2019.
[2] WO2013018990, "Lipid-based drug delivery systems for CNS targeting."
[3] US20140233456, "Benzodiazepine derivatives for neuropsychiatric applications."
[4] EP3478901, "Lipid formulations for CNS drug delivery," pending or granted patent covering similar compositions in Europe.
